- Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPF
- Additional presentations include preclinical and translational data reflecting the potency of buloxibutid’s upstream mechanism of action as well as the design of the upcoming Phase 2b ASPIRE trial
- Vicore also to be featured in a poster presentation at the ATS Respiratory Innovation Summit
“We are pleased to showcase a series of presentations at the upcoming
“In the previously disclosed interim results of the Phase 2a AIR trial, buloxibutid demonstrated the ability to stabilize and subsequently improve lung function as measured by forced vital capacity, in individuals with the life-shortening disease, idiopathic pulmonary fibrosis” said
Vicore’s abstracts for the conference are available on the ATS’s 2024 online program:
Oral, Late-Breaking Presentation
Mini Symposium A18: Fixing What’s Broken: Novel Therapeutics for
Date:
Presentation Time:
Location:
Abstract: Buloxibutid, a Novel Angiotensin II Type 2 Receptor Agonist, Stabilized and Improved Lung Function in Individuals with Idiopathic Pulmonary Fibrosis in the 36-week Phase 2 AIR Trial
Poster Presentation
Poster Discussion Session B30: Scarred for Life:
Date:
Presentation Time:
Location:
Abstract: Deciphering the Clinical Efficacy Mechanisms of Buloxibutid in Idiopathic Pulmonary Fibrosis
Poster Presentation
Thematic Poster Session B48: New Treatments in Diffuse Parenchymal Lung Disease
Date:
Presentation Time:
Location:
Abstract: Crafting a Patient-focused Phase 2b Trial (ASPIRE) to Evaluate Efficacy and Safety of Buloxibutid in Individuals with Idiopathic Pulmonary Fibrosis (IPF)
In addition to these presentations, Vicore will be featured as a poster presented at the ATS 2024 Respiratory Innovation Summit, a meeting attracting representatives from pharma business development, venture capital, government, academia, and clinical medicine, on
For further information, please contact:
This information was submitted for publication on
About
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.
About the AIR trial
AIR is a single arm Phase 2a trial of buloxibutid in idiopathic pulmonary fibrosis (IPF). The trial includes centrally read high resolution computerized tomography (HRCT) to establish the diagnosis of IPF and spirometry in line with
© Modular Finance, source